Key result
The HTR2C rs1414334 C allele was significantly associated with metabolic syndrome in patients with schizophrenia (pooled OR 2.35; 95% CI 1.19-4.62), particularly those using clozapine or risperidone.
Why the study?
Do HTR2C gene polymorphisms increase the risk of metabolic syndrome in patients with schizophrenia using antipsychotics?
Cross-Sectional (n=276)
Do HTR2C gene polymorphisms increase the risk of metabolic syndrome in patients with schizophrenia using antipsychotics?
Odds Ratio: 2.35 (95% CI 1.19–4.62)
The rs1414334 C allele of the HTR2C gene is associated with an increased risk of metabolic syndrome in patients with schizophrenia, particularly those treated with clozapine or risperidone.
No takes yet. Share an insight, caveat, or question.
Supports closer metabolic monitoring for rs1414334 C carriers on clozapine or risperidone; hypothesis-generating pending prospective validation.
Mulder et al. (2009) conducted a cross-sectional in Schizophrenia (n=276). HTR2C gene polymorphisms (rs1414334 C allele) vs. Non-carriers was evaluated on Prevalence of the metabolic syndrome (OR 2.35, 95% CI 1.19-4.62). The HTR2C rs1414334 C allele was significantly associated with metabolic syndrome in patients with schizophrenia (pooled OR 2.35; 95% CI 1.19-4.62), particularly those using clozapine or risperidone.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: